Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(2)

Detailed Status

Completed2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed250%

terminated250%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_1

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

NCT02400242

terminatedphase_1

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

NCT02635061

completedphase_1

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT02551185

completedphase_1

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790

Clinical Trials (4)

Showing 4 of 4 trials

NCT02400242Phase 1

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Terminated

NCT02635061Phase 1

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Terminated

NCT02551185Phase 1

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Completed

NCT02935790Phase 1

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4